177 related articles for article (PubMed ID: 33832957)
1. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial.
Qu L; Liang X; Tian G; Zhang G; Wu Q; Huang X; Cui Y; Liu Y; Shen Z; Xiao C; Qin Y; Miao H; Zhang Y; Li Z; Ye S; Zhang X; Yang J; Cao G; Li Y; Yang G; Hu J; Wang X; Li Z; Li Y; Zhang X; Zhang G; Chen L; Hua W; Yu M; Lu C; Zhang X; Jiang H
Diabetes Care; 2021 Jun; 44(6):1324-1333. PubMed ID: 33832957
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for Treatment of Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Multicenter Clinical Study.
Qu L; Liang XC; Tian GQ; Zhang GL; Wu QL; Huang XM; Cui YZ; Liu YL; Shen ZF; Ma GQ; Lu H; Li Y; Jiang H; Yang XY; Zhang GD; Yang CH
Chin J Integr Med; 2022 Apr; 28(4):304-311. PubMed ID: 35048240
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blinded, Double-Dummy, Active-Controlled, and Multiple-Dose Clinical Study Comparing the Efficacy and Safety of Mulberry Twig (Ramulus Mori, Sangzhi) Alkaloid Tablet and Acarbose in Individuals with Type 2 Diabetes Mellitus.
Li M; Huang X; Ye H; Chen Y; Yu J; Yang J; Zhang X
Evid Based Complement Alternat Med; 2016; 2016():7121356. PubMed ID: 27547230
[TBL] [Abstract][Full Text] [Related]
4. Effects of mulberry twig alkaloids(Sangzhi alkaloids) and metformin on blood glucose fluctuations in combination with premixed insulin-treated patients with type 2 diabetes.
Meng Z; Xu C; Liu H; Gao X; Li X; Lin W; Ma X; Yang C; Hao M; Zhao K; Hu Y; Wang Y; Kuang H
Front Endocrinol (Lausanne); 2023; 14():1272112. PubMed ID: 38027146
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive: A multicentre, randomized, open-label, prospective study (ACADEMIC).
Gao B; Gao W; Wan H; Xu F; Zhou R; Zhang X; Ji Q
Diabetes Obes Metab; 2022 Jun; 24(6):991-999. PubMed ID: 35112779
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: a multicentre, randomized, double-blinded, double-dummy positive controlled trial.
Wu QL; Liu YP; Lu JM; Wang CJ; Yang T; Dong JX; Li CJ; Ma JH; Xue YM; Sun RH; Wei D; Tian HM
J Evid Based Med; 2012 Aug; 5(3):134-8. PubMed ID: 23672220
[TBL] [Abstract][Full Text] [Related]
7. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
[TBL] [Abstract][Full Text] [Related]
9. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
[TBL] [Abstract][Full Text] [Related]
10. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.
Coniff RF; Shapiro JA; Seaton TB; Hoogwerf BJ; Hunt JA
Diabetes Care; 1995 Jul; 18(7):928-32. PubMed ID: 7555551
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial.
Jabbour SA; Frías JP; Hardy E; Ahmed A; Wang H; Öhman P; Guja C
Diabetes Care; 2018 Oct; 41(10):2136-2146. PubMed ID: 30082326
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study.
Kim SS; Kim IJ; Lee KJ; Park JH; Kim YI; Lee YS; Chung SC; Lee SJ
J Diabetes; 2017 Apr; 9(4):412-422. PubMed ID: 27229178
[TBL] [Abstract][Full Text] [Related]
16. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Rodbard HW; Lingvay I; Reed J; de la Rosa R; Rose L; Sugimoto D; Araki E; Chu PL; Wijayasinghe N; Norwood P
J Clin Endocrinol Metab; 2018 Jun; 103(6):2291-2301. PubMed ID: 29688502
[TBL] [Abstract][Full Text] [Related]
17. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin.
Phillips P; Karrasch J; Scott R; Wilson D; Moses R
Diabetes Care; 2003 Feb; 26(2):269-73. PubMed ID: 12547847
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
Halimi S; Le Berre MA; Grangé V
Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes.
Kelley DE; Bidot P; Freedman Z; Haag B; Podlecki D; Rendell M; Schimel D; Weiss S; Taylor T; Krol A; Magner J
Diabetes Care; 1998 Dec; 21(12):2056-61. PubMed ID: 9839094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
